A EGFR tyrosine kinase inhibitor named osimertinib, its production process has been proven a important advancement within the drug industry.Additionally, called Tagrisso, the drug, it is mainly used in treating NSCLC (NSCLC) where the condition includes EGFR alterations.The chemical production of osimertinib is an complex process encompassing several challenging steps that need precision and expertise.The article discusses the complexity of the osimertinib synthesis, pinpointing significant challenges and advancements achieved within the domain.It's a complex synthesis process of osimertinib that faces multiple difficulties.The main difficulty lies in the complexity of the…
